Fig. 2

Bmpr2 mutant rats are phenotypically similar to wild-type rats at 21 days after MCT injection. All the measurements are done in male rats with wild-type (WT) and Bmpr2 mutation (+/44insG) at 3 weeks after monocrotaline (MCT [3 wk]) or saline injection (Control). A Mean pulmonary artery pressure (mPAP) (n = 37, WT and +/44insG), B the weight ratio of right ventricle/left ventricle plus septum (RV/[LV + S]) (n = 43 WT and +/44insG) and C systolic aortic pressure (Sys AOP) (n = 37, WT and +/44insG) at 3 weeks after MCT or saline injection. D The quantification of percentage muscularisation of distal PAs (n = 21, WT and +/44insG). E and F Representative images of the distal PAs and the quantification of the number of distal PAs per 100 alveoli (n = 23, WT and +/44insG) assessed in control and MCT-treated rats. Scale bar: 200 μm (G–I) Representative images of barium filled PAs with diameter 100–200 μm (G), 50–100 μm (H), 15–50 μm (I) in control (top images) and MCT-treated rats at 3 weeks (bottom images) and the quantification of medial wall thickness (MWT) (n = 22, WT and +/44insG). Scale bar: 50 μm (F and G), 25 μm (H). The numbers in parentheses represent the numbers of rats examined. Data are presented as means ± SEM; one-way ANOVA followed by Bonferroni’s multiple comparison test; *: P < 0.01 vs Control, WT; †: P < 0.01 vs Control, +/44insG. mPAP = mean pulmonary artery pressure; RV/(LV + S) = weight ratio of right ventricle/left ventricle plus septum; Sys AOP = systolic aortic pressure; WT = wild-type; +/44insG = rats with bone morphogenetic protein receptor type 2 mutation; MCT = Monocrotaline; PAs = Pulmonary arteries; %MWT = percentage of medial wall thickness; wk = weeks; mPAP = mean pulmonary artery pressure; RV/(LV + S) = weight ratio of right ventricle/left ventricle plus septum; WT = wild-type; +/44insG = rats with bone morphogenetic protein receptor type 2 mutation; MCT = Monocrotaline; PAs = Pulmonary arteries; %MWT = percentage of medial wall tension; wk = weeks